146 related articles for article (PubMed ID: 33099182)
21. Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.
Catcott KC; McShea MA; Bialucha CU; Miller KL; Hicks SW; Saxena P; Gesner TG; Woldegiorgis M; Lewis ME; Bai C; Fleming MS; Ettenberg SA; Erickson HK; Yoder NC
MAbs; 2016; 8(3):513-23. PubMed ID: 26752675
[TBL] [Abstract][Full Text] [Related]
22. Combretastatin A4-derived payloads for antibody-drug conjugates.
Huang R; Sheng Y; Xu Z; Wei D; Song X; Jiang B; Chen H
Eur J Med Chem; 2021 Apr; 216():113355. PubMed ID: 33721668
[TBL] [Abstract][Full Text] [Related]
23. A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation.
Yoder NC; Bai C; Tavares D; Widdison WC; Whiteman KR; Wilhelm A; Wilhelm SD; McShea MA; Maloney EK; Ab O; Wang L; Jin S; Erickson HK; Keating TA; Lambert JM
Mol Pharm; 2019 Sep; 16(9):3926-3937. PubMed ID: 31287952
[TBL] [Abstract][Full Text] [Related]
24. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
25. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Oroudjev E; Lopus M; Wilson L; Audette C; Provenzano C; Erickson H; Kovtun Y; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2700-13. PubMed ID: 20937595
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.
Lai KC; Deckert J; Setiady YY; Shah P; Wang L; Chari R; Lambert JM
Pharm Res; 2015 Nov; 32(11):3593-603. PubMed ID: 25630819
[TBL] [Abstract][Full Text] [Related]
27. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
28. Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.
Gébleux R; Wulhfard S; Casi G; Neri D
Mol Cancer Ther; 2015 Nov; 14(11):2606-12. PubMed ID: 26294742
[TBL] [Abstract][Full Text] [Related]
29. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
30. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions.
Fishkin N; Maloney EK; Chari RV; Singh R
Chem Commun (Camb); 2011 Oct; 47(38):10752-4. PubMed ID: 21874179
[TBL] [Abstract][Full Text] [Related]
31. Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates.
Huang R; Sheng Y; Wei D; Lu W; Xu Z; Chen H; Jiang B
Bioorg Med Chem; 2020 Dec; 28(23):115793. PubMed ID: 33039798
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.
Zhao RY; Wilhelm SD; Audette C; Jones G; Leece BA; Lazar AC; Goldmacher VS; Singh R; Kovtun Y; Widdison WC; Lambert JM; Chari RV
J Med Chem; 2011 May; 54(10):3606-23. PubMed ID: 21517041
[TBL] [Abstract][Full Text] [Related]
33. SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.
Hamblett KJ; Jacob AP; Gurgel JL; Tometsko ME; Rock BM; Patel SK; Milburn RR; Siu S; Ragan SP; Rock DA; Borths CJ; O'Neill JW; Chang WS; Weidner MF; Bio MM; Quon KC; Fanslow WC
Cancer Res; 2015 Dec; 75(24):5329-40. PubMed ID: 26631267
[TBL] [Abstract][Full Text] [Related]
34. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
[TBL] [Abstract][Full Text] [Related]
35. UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads.
Pysz I; Jackson PJM; Barlow DJ; Rahman KM; Thurston DE
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1146():122075. PubMed ID: 32361467
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V
Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521
[TBL] [Abstract][Full Text] [Related]
37. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
38. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
39. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
40. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
